Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. released partial results from their first of three exenatide Phase III trials in Type II diabetes, disclosing enough information to show the product hit its primary endpoint and to raise Amylin's stock. (BioWorld Today) Read More
